➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Dow
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IDHIFA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Idhifa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03515512 ↗ IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting Celgene Phase 1 2018-07-17 This research study is studying a targeted therapy drug as a possible treatment for IDH2 mutant acute myeloid leukemia or chronic myelomonocytic leukemia while undergoing hematopoietic stem cell transplantation. The drug involved in this study is: -Enasidenib.
NCT03515512 ↗ IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting Massachusetts General Hospital Phase 1 2018-07-17 This research study is studying a targeted therapy drug as a possible treatment for IDH2 mutant acute myeloid leukemia or chronic myelomonocytic leukemia while undergoing hematopoietic stem cell transplantation. The drug involved in this study is: -Enasidenib.
NCT03683433 ↗ Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting National Cancer Institute (NCI) Phase 2 2018-09-18 This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back or does not respond to treatment. Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Idhifa

Condition Name

Condition Name for Idhifa
Intervention Trials
Recurrent Acute Myeloid Leukemia 4
IDH2 Gene Mutation 4
Acute Myeloid Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Idhifa
Intervention Trials
Leukemia, Myeloid, Acute 6
Leukemia, Myeloid 6
Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Idhifa

Trials by Country

Trials by Country for Idhifa
Location Trials
United States 7
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Idhifa
Location Trials
California 2
Illinois 1
Tennessee 1
Florida 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Idhifa

Clinical Trial Phase

Clinical Trial Phase for Idhifa
Clinical Trial Phase Trials
Phase 2 3
Phase 1/Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Idhifa
Clinical Trial Phase Trials
Not yet recruiting 7
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Idhifa

Sponsor Name

Sponsor Name for Idhifa
Sponsor Trials
National Cancer Institute (NCI) 4
Celgene 3
Jonsson Comprehensive Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Idhifa
Sponsor Trials
Other 7
Industry 5
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Mallinckrodt
Boehringer Ingelheim
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.